Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy can fight prostate cancer by androgen deprivation. It is not yet known if neoadjuvant radiation therapy is a more effective therapy for high-risk prostate cancer. PURPOSE: Two-stage randomized trial to compare the effectiveness and safety of neoadjuvant radiotherapy and hormone therapy followed by radical prostatectomy in men with high-risk locally advanced prostate cancer

Trial Details

NCT ID
NCT04894188
Phase
NA
Sponsor
National Taiwan University Hospital
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • radiation therapy
  • Goserelin 3.6 MG
  • radical prostatectomy
Locations (sample)
  • Douliu City/Huwei Township, Yunlin County, Taiwan
  • Tapiei, Taiwan

Key Eligibility Criteria

  • Men with age from 20 to 75 years old
  • Signed an informed consent form (ICF) indicating that the subject understands the purpose of and procedures required for the study and is willing t…
  • Histologically confirmed adenocarcinoma of the prostate
  • High-risk locally advanced disease defined by ≥1 of the following 3 criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →